Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 6-7, Juin–Juillet 2005
Page(s) 613 - 617
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005216-7613
Publié en ligne 15 juin 2005
  1. Pavlou AK, Reichert JM. Recombinant protein therapeutics: success rates, market trends and values to 2010. Nat Biotechnol 2004; 22 : 1513–9.
  2. Braun P, LaBaer J. High throughput protein production for functional proteomics. Trends Biotechnol 2003; 21 : 383–8.
  3. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22 : 346–53.
  4. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2 : 52–62.
  5. Gerngross TU. Advances in the production of human therapeutic proteins in yeast and filamentous fungi. Nat Biotechnol 2004; 22 : 1409–14.
  6. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22 : 1393–8.
  7. Hellwig S, Drossard J, Twyman RM, Fischer R. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004; 22 : 1415–22.
  8. Ritz D, Beckwith J. Roles of thiol-redox pathways in bacteria. Annu Rev Microbiol 2001; 55 : 21–48.
  9. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochem Biophys Acta 2004; 1699 : 35–44.
  10. Spirin AS. High-throughput cell-free systems for synthesis of functionally active proteins. Trends Biotechnol 2004; 22.
  11. Betton JM. Rapid translation system (RTS): a promising alternative for recombinant protein production. Curr Protein Pept Sci 2003; 4 : 73–80.
  12. Braun P, Hu Y, Shen B, et al. Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Sci USA 2002; 99 : 2654–9.
  13. Kiefhaber T, Rudolph R, Kohler H-H, Buchner J. Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology 1991; 9 : 825–9.
  14. Fink AL. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Design 1998; 3 : R9–23.
  15. Carrio MM, Villaverde A. Construction and deconstruction of bacterial inclusion bodies. J Biotechnol 2002; 96 : 3–12.
  16. Fischer G, Tradler T, Zarnt T. The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding versus catalysis. FEBS Lett 1998; 426 : 17–20.
  17. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 1999; 286 : 1888–93.
  18. Middelberg APJ. Preparative protein refolding. Trends Biotechnol 2002; 20 : 437–43.
  19. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 2004; 22 : 1399–408.
  20. Clark ED, Schwartz E, Rudolph R. Inhibition of aggregation side reactions during in vitro protein folding. Meth Enzymol 1999; 309 : 217–36.
  21. Waldo GS, Standish BM, Berendzen J, Terwilliger TC. Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol 1999; 17 : 691–5.
  22. Cabantous S, Terwilliger TC, Waldo GS. Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. Nat Biotechnol 2005; 23 : 102–7.
  23. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22 : 1383–91.
  24. Zhang Z, Gildersleeve J, Yang YY, et al. A new strategy for the synthesis of glycoproteins. Science 2004; 303 : 371–3.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.